Denmark
16 articles on Denmark, researched and written by the Shotlee Editorial Team from primary sources.
Study Links Hormonal Birth Control Use to Higher Likelihood of Needing Weight Loss Injections
A recent Danish study suggests that women who have used hormonal birth control may be more likely to seek weight loss injections such as Wegovy and Ozempic. This research sheds light on a long-reported, yet often unproven, connection between contraceptives and weight changes.
7 min read
The Workforce Runs on Weight Loss Drugs? Employees on GLP-1s Take Fewer Sick Days
Employees on GLP-1 medications are taking significantly fewer sick days, leading to cost savings and improved productivity. A new study reveals the economic and health impacts of drugs like Ozempic and Wegovy on the workforce.
9 min read
The Workforce Runs on Weight Loss Drugs? Employees on GLP-1s Take Fewer Sick Days
A new study reveals significant reductions in long-term sick leave for workers taking GLP-1 medications, offering insights into workplace productivity and long-term health savings.
10 min read
Denmark's Obesity Rate Stalls in Wegovy-Maker Novo's Home Market
Obesity levels have plateaued in Denmark at 18.5% among adults and older teens in 2025, unchanged from 2021 after years of rises from 13.6% in 2010. Novo Nordisk launched Wegovy there in late 2022, with 270,000 users—nearly 5% of the population—potentially shifting trends away from 32% by 2040 projections. Experts credit GLP-1 drugs like Wegovy and Ozempic alongside lifestyle factors.
4 min read
New Diet Lowers Methionine & Cysteine to Trigger Fat Burning Without Exercise
Lab mice shed pounds when key amino acids—methionine and cysteine—were cut from their diet, igniting fat burning without exercise. A University of Southern Denmark study shows this diet-induced thermogenesis boosted calorie burn by 20%, nearly matching constant cold exposure. This could redefine obesity treatments beyond GLP-1 drugs.
6 min read
Novo's Woes Despite Ozempic's Explosive Growth
Novo Nordisk's Ozempic pioneered the GLP-1 revolution, tripling sales to 309 billion DKK in eight years. Yet shares have cratered 60% due to Eli Lilly's Mounjaro gains, trial disappointments, and looming generics. Discover the booming market's challenges and opportunities.
5 min read
$3,000 Minipigs Powering Europe's Drug Pipeline
In eastern Denmark, Ellegaard Gottingen Minipigs A/S breeds specialized $3,000 minipigs vital to Europe's drug pipeline, including Novo Nordisk's Ozempic and Wegovy. These biosecure facilities address supply chain vulnerabilities exposed by the pandemic's monkey shortages. As the EU pushes for biotech independence, these smaller, human-like pigs offer a strategic alternative.
6 min read
SAPS Official Sought Ozempic from Boyfriend's Company
A senior South African Police Service official admitted under oath to asking her boyfriend's company for Ozempic amid pharmacy shortages. Brigadier Rachel Matjeng's testimony at the Madlanga Commission highlights the drug's high demand for type 2 diabetes and off-label weight loss use. The case raises questions about procurement ethics in a corruption inquiry.
5 min read
GLP-1 Kidney Risks: Study Compares Ozempic to SGLT2 Drugs
A recent Danish study in JAMA Internal Medicine highlights higher kidney risks with popular GLP-1 drugs like Ozempic compared to SGLT2 inhibitors. While GLP-1s offer weight loss benefits, understanding these findings is crucial for patients. Learn the science, risks, and how to protect your kidneys.
5 min read
GLP-1 Nutrition Boosters: Pharma & Startup Innovations
GLP-1 medications like Ozempic and Wegovy are transforming weight management, but side effects like gut issues and muscle loss demand smart support. Nutrition and pharma startups are stepping up with targeted innovations to enhance results and minimize risks. Learn how binding proteins, protein enzymes, and novel inhibitors create a comprehensive ecosystem for long-term success.
4 min read
GLP-1 Drugs Reshaping Eating Habits in Connecticut
GLP-1 weight-loss drugs like Ozempic and Wegovy are changing how people in Connecticut eat, boosting demand for protein-rich foods to combat muscle loss. Nutrition experts and restaurateurs note shifts toward balanced meals and smaller portions. A clinical epidemiologist reveals how these drugs suppress appetite and delay gastric emptying for significant weight reduction.
4 min read
GLP-1 Receptor Agonists and Next-Generation Metabolic Hormone Therapies for Chronic Kidney Disease
Clinical trials across the cardiovascular-kidney-metabolic spectrum demonstrate kidney protective effects of incretin-based therapies. Multiple studies show GLP-1RAs and dual GIP/GLP-1RAs reduce kidney disease progression, albuminuria, and kidney failure risk in patients with type 2 diabetes and chronic kidney disease.
10 min read
Tablets, TikTok, and Weight-Loss Applications: The Consumer-Centric Upcoming Era of GLP-1 Medications
The landscape of GLP-1 medications for weight loss is shifting towards consumer-driven models, with pill versions offering flexibility and telehealth platforms making access easier. Industry experts envision daily routines incorporating these drugs alongside apps, while concerns arise about medical oversight and long-term effects. This evolution could expand the market significantly, driven by affordability and marketing.
6 min read
Pills, TikTok, and Weight-Loss Apps: The Consumer-Focused Evolution of GLP-1 Drugs
The future of GLP-1 drugs for weight loss involves daily pills, smartphone apps for dose management, and easy access through telehealth, mirroring consumer goods like streaming services. As Novo Nordisk and Eli Lilly prepare pill versions, the obesity market could expand to $150 billion by the next decade. This shift emphasizes convenience, affordability, and lifestyle integration, but raises concerns about medical oversight and safety.
6 min read
Danish Elections: Voting Information for Municipalities and Regions
Municipal and regional elections are scheduled across Denmark. Eligible residents can vote by visiting their designated polling station with a valid ID. Numerous international residents also qualify to participate.
1 min read
The Heated Race to Dominate the Booming GLP-1 Medication Arena
The GLP-1 drug market is experiencing rapid growth, driven by the increasing demand for treatments for type 2 diabetes and obesity. Three major pharmaceutical companies are vying for market dominance.
3 min read